InxMed

Focus: InxMed is a Beijing-based oncology-focused biotech founded in 2018, currently public with 1-50 employees and a pipeline concentrated on IN10018 across multiple solid tumor indications.

Oncology

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Employees

1-50

Open Jobs

About InxMed

AI assessmentNot Hiring

No open roles listed right now. Follow InxMed to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

3/9 — Basic

Company HealthSolid

Pipeline

Mid-stage

1 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

IN10018

Metastatic Melanoma

PHASE_1

Clinical Trials (1)

NCT04109456IN10018 Monotherapy and Combination Therapy for Metastatic Melanoma

Phase 1

Help build intelligence for InxMed

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Early-stage oncology biotech with 13 active trials spanning Phase 1-3, offering ground-floor opportunity to shape clinical development strategy
Focused pipeline with lead asset IN10018 advancing in multiple indications including Phase 3 NSCLC combination study, providing clear near-term catalysts
Public company status enables potential equity upside and operational transparency despite micro-cap scale

Watch Out For

Micro-cap structure (1-50 employees) with only 4 active job openings suggests severely constrained resources and limited career infrastructure
Early-stage pipeline (11 Phase 1 programs, only 1 Phase 3) creates execution risk; most programs remain unproven and years from potential approval
Undisclosed financials and no revenue data visible—cash runway and sustainability unknown, raising questions about long-term viability

Generated by Claude from InxMed's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

IN10018

Gastric Cancer

PHASE_1

Clinical Trials (1)

NCT05327231IN10018 Monotherapy or in Combination With Docetaxel in Gastric or GEJ Adenocarcinoma

Phase 1

IN10018

Pancreatic Cancer

PHASE_1_2

Clinical Trials (1)

NCT05827796IN10018+ Standard Chemotherapy (+KN046) in Subjects With Advanced Pancreatic Cancer

Phase 1/2

IN10018 in combination with RNK08954

Solid Tumor Cancer

PHASE_1_2

Clinical Trials (1)

NCT07441174IN10018 in Combination With RNK08954 for the Treatment of KRASG12D Mutation-Positive Locally Advanced or Metastatic Solid Tumors

Phase 1/2

D-1553

Solid Tumor

PHASE_1_2

Clinical Trials (1)

NCT05379946Study to Evaluate D-1553 in Combination With IN10018 in Subjects With Solid Tumors

Phase 1/2

IN10018

Solid Tumor

PHASE_1_2

Clinical Trials (1)

NCT05982522IN10018 Combination Therapy in Previously-treated Solid Tumors

Phase 1/2

IN10018

Small Cell Lung Cancer Extensive Stage

PHASE_1_2

Clinical Trials (1)

NCT06030258IN10018 Combination Therapy in Treatment-naïve ES-SCLC

Phase 1/2

IN10018

NSCLC

PHASE_1_2

Clinical Trials (1)

NCT05994131IN10018 Combination Therapy in Advanced EGFR Mutation-positive NSCLC

Phase 1/2

IN10018+PLD

Locally Advanced or Metastatic Solid Tumors

PHASE_1_2

Clinical Trials (1)

NCT05830539IN10018 Combination Therapy in Previously-treated Locally Advanced or Metastatic Solid Tumor Patients

Phase 1/2

IN10018 in combination with PLD

Platinum-resistant Ovarian Cancer

PHASE_1_2

Clinical Trials (1)

NCT05551507IN10018 in Combination With Standard Chemotherapy in High-grade Serous Epithelial Ovarian Cancer

Phase 1/2

D1553

Solid Tumor

PHASE_1_2

Clinical Trials (1)

NCT06166836a Study to Evaluate the Safety and Efficacy of D-1553 Combined With IN10018 in KRAS G12C Mutant Solid Tumors

Phase 1/2

IN10018

Ovarian Cancer Recurrent

PHASE_2

Clinical Trials (1)

NCT06014528IN10018 in Combination With Pegylated Liposomal Doxorubicin (PLD) vs. Placebo in Combination With PLD for the Treatment of Platinum-resistant Recurrent Ovarian Cancer

Phase 2

IN10018 in combination with D-1553

Non-Small Cell Lung Cancer

PHASE_3

Clinical Trials (1)

NCT07174908A Phase 3 Study of IN10018 in Combination With D-1553 Versus Standard Therapy for First Line Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation

Phase 3

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Founded: 2018

Portfolio: 13 clinical trials

Top TAs: Oncology

Publications: 11 in PubMed

Therapeutic Area Focus

Oncology

13 pipeline

Marketed

Pipeline

Research Publications(10)

Recent peer-reviewed publications with author affiliations at this company

Targeting FAK improves the tumor uptake of antibody-drug conjugates to strengthen the anti-cancer responses.

iScience

2025

PMID:40040813

Prospects of focal adhesion kinase inhibitors as a cancer therapy in preclinical and early phase study.

Expert opinion on investigational drugs

Showing 5 of 10 publications

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

InxMed

About InxMed

Why Work Here

Pipeline & Clinical Trials

Watch Out For

Recent News · InxMed(1)

Open Jobs (0)

Research Publications(10)